Pharma firm Laurus Labs on Friday said it has obtained the licence from Defence Research and Development Organisation to produce and market COVID-19 treatment drug 2-Deoxy-D-Glucose (2DG).
2DG has been given disaster authorization by the Drugs Controller General of India (DCGI) for use on COVID-19 patients in the nation, Laurus Labs said in a regulatory filing . “Laurus Labs has already applied with the Central Drugs Standard Control Organisation (CDSCO) for emergency use authorization (EUA) for 2DG,” it added.
On June 28, pharma key Dr Reddy’s declared the commercial start of 2DG at a maximum retail price of Rs 990 per sachet. Shares of Laurus Labs were trading at Rs 674.20 per scrip on BSE, up 1.08 per cent from the previous close.